Company Profile
Updated: 30-OCT-09Apogepha Arzneimittel GmbH
International Private company
Kyffhaeuserstrasse 27, Dresden, D-01309, Germany
()49 0351 33 633, 49 0351 33 63 440 fax, http://www.apogepha.de
Primary SIC: Medical Chemicals & Botanical Products, Primary NAICS: Medicinal and Botanical Manufacturing
Description: Manufacturing: Pharmaceutical company
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Japan stock market week to Jan 22, 2007.(Statistical data)
Pharma Marketletter; 1/29/2007; 1091 words; ...lost 0.2% because it terminated an agreement with APOGEPHA Arzneimittel GmbH of Germany for the development and marketing of NS...results of the proof-of-concept study conducted by APOGEPHA in Europe. These did not show sufficient efficacy...
Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder
JCNN News Summaries - Japan Corporate News Network; 1/25/2007; 356 words; ...JCN) - Nippon Shinyaku and Apogepha Arzneimittel GmbH announced on January 16 their...Concept study undertaken by Apogepha in Europe. NS-8 is a novel...Shinyaku and was licensed out to Apogepha in October 2003. Apogepha has...
Amdipharm gains UK rights for Detrunorm.(Brief Article)
Pharma Marketletter; 7/26/2004; 513 words; ...Detrunorm (propiverine), from Germany-based Apogepha Arzneimittel GmbH. The agent was previously licensed to Schering...Under the terms of the accord, the UK firm will pay Apogepha an undisclosed single cash payment. Upon transfer...
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning
